Bioventix Announcements

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the [...]

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual [...]

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2021

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Interim results can be found here and are as stated below.   Highlights Revenue up 1.3% to £5.2 million (2019: £5.1 million) Profit before tax down 9% to £3.7 million (2019: £4.1 million) [...]

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed. Download as pdf.

Bioventix plc (BVXP) confirms that its Annual Report and Accounts for the year ended 30 June 2020 and the Notice of Annual General Meeting (“AGM”) has been posted to shareholders.